Trial reportCurrent oncology (Toronto, Ont.)2024
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA).
Trial report in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials.World journal of surgical oncology · 2025Pooled it
- Hyperthermic intraperitoneal chemotherapy in ovarian cancer: a comprehensive review.Frontiers in oncology · 2025Pooled it
- The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).Journal of ovarian research · 2024Trial
- A Meta-Analysis on the Long-Term Impact of Cytoreductive Surgery Plus HIPEC for Ovarian Cancer with Peritoneal Metastasis: Are We on the Right Path?Life (Basel, Switzerland) · 2026Review
- Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer.JAMA network open · 2025Article
- An Updated Meta-Analysis on Long-Term Outcomes Following Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer.Cancers · 2025Review
- Review
- Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.Journal of clinical medicine · 2025Article
- Article
- Research progress in endometriosis-associated ovarian cancer.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcomes for the HIPEC (RFS: 23 months, OS: 48 months) over the control group (RFS: 19 months, OS: 46 months), these differences were not statistically significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.